Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.51 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14247675 | 0.83 | ADRA1A (0.49) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL28806293 | 0.83 | ADRA1A (0.49) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL29842306 | 0.82 | GID4 (0.62) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL395087 | 0.82 | GID4 (0.62) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL29100087 | 0.81 | GID4 (0.50) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL4204524 | 0.80 | ADRA1A (0.59) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL11696770 | 0.79 | IDO1 (0.51) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL10501682 | 0.79 | ADRA2A (0.50) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL10359793 | 0.79 | GID4 (0.51) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B | |
| SCHEMBL3955741 | 0.77 | ADRA1A (0.65) | ADRA2AADRA1ACYP2D6ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598483-B1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2391616-B1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2231666-B1 | Carboxamide, sulfonamide and amine compounds for metabolic disorders | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2231600-B1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015048547-A2 | METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-8980921-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8809370-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130267702-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2013-10-10 | — | — | US | disclosed |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2391616-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2231666-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231600-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010088392-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2079694-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | Rigel Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009065131-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008083124-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | ADRA2A 792/4885ADRA1A 872/4885CYP2D6 2127/4885 |
| US-20130267702-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | ADRA2A 792/4885ADRA1A 872/4885CYP2D6 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.